Patient enrollment underway in phase 2 study of novel dry eye treatment
Click Here to Manage Email Alerts
The first patient has been enrolled in a phase 2 clinical study evaluating YP-P10 for the treatment of dry eye disease, according to a press release from Yuyu Pharma.
The ICECAP study will include 240 patients at seven U.S. sites and assess the safety, tolerability and efficacy of YP-P10, a novel synthetic peptide with anti-inflammatory and wound healing properties. Earlier this year, the FDA cleared an investigational new drug application for the ophthalmic solution.
According to preclinical data, YP-P10 lowered proinflammatory cytokines and chemokines production in human peripheral blood mononuclear cells.
“We are pleased to enroll our first patient in ICECAP 1, the phase 2 clinical study of YP-P10 ophthalmic solution,” Robert Yu, CEO of Yuyu Pharma, said in the release. “This is our first
biopharmaceutical clinical trial within the United States, and we are enthusiastic about
its potential to assist patients with DED who struggle to find lasting relief with alternative
therapies currently available in the market.”
Read more about
Click Here to Manage Email Alerts